Get started
NRX Pharmaceuticals, Inc.NN

NRX Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

NRXP trade ideas

NRXP - long - catalyst playNRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. This is not a financial advice! Upcoming catalysts 03/31/2024 and 06/30/2024 Today Rel. Vol. of 12.66 We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. Keep an eye on 1.0, 1.5 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains. SL under 0.5 TPs approx. 2.20 Most info on the chart. Trade carefully!
NASDAQ:NRXPLong
by meitshels_smell_trades
$NRXP NRX Pharmaceuticals Inc NASDAQ:NRXP NRX Pharmaceuticals Inc Long term PTs 1.20 - 1.50 - 3.50 - 10 and higher NRx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company has a joint Agreement with Nephron Pharmaceuticals, Inc. to develop intravenous ketamine to treat suicidal depression. The company was founded in 2015 and is based in Wilmington, Delaware.
NLong
by BADQOMOCAWGOWLD
NRX Pharma USASun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series Focus: Worldwide By Sun Storm Investment Research & NexGen Wealth Management Service A Profit & Solutions Strategy & Research Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures | USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision. #debadipb #profitsolutions
N
by Sunstorminvest
#NRXP 12-22-66 NRX Pharmaceuticals (NRXP) said Friday data from a mid-stage trial showed that the BriLife COVID19 vaccine may be able to protect against the delta variant of SARS-CoV-2, the virus that causes COVID-19. In the phase 2 study, 10 out of the 11 samples taken from participants to be tested for antibodies were found to neutralize the delta variant. Data suggests that the vaccine may be capable of evolving to counter delta and other variants of concern, the company said. The company expects to start a phase 2b/3 registration trial of the vaccine after a review of the phase 2 study results by the data safety monitoring board. It is developing BriLife under an exclusive license from the Israel Ministry of Defense.
NLong
by KAPRUKA
NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant. Information was released by Israel Institute for Biological Research. Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines. I consider this a premium call, the upside i see here is 400%, or the 24usd resistance. NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd. Is this a buy or not? Market Cap of only 396.97Mil
NLong
by TopgOptions
1
#NRXP Huge Gain May Reach $64 Sector: Health Technology Industry: Pharmaceuticals: Major NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE. NRx Pharmaceuticals (NRXP) said Tuesday it has submitted a revised investigational new drug module with the US Food and Drug Administration confirming that Nephron Pharmaceuticals is ready to supply its COVID-19 drug candidate Zyesami on a commercial scale. The FDA will include the module in its rolling review of the new drug application for Zyesami, the company said. NRx also recently received notification that inspection at a separate manufacturing facility for Zyesami in Europe has been completed. It is now awaiting QP Declaration, which is required by the EU regulatory authorities for the release of the drug. Shares in the drugmaker rose 3.1% in Tuesday premarket trading. New Target : USD 64 Resistance 3 : USD 49.20 Resistance 2 : USD 26.27 Resistance 1 : USD 11.06 Support Level : USD 6.17 **Disclaimer - This is not a financial advice, please trade with caution and on your own risk. This prediction Based on My Dreams. Do not view this idea as a recommendation for trading or investing. Risk Only What You Can Afford. Always Use a Stop Loss. Past performance is not necessarily a guide to future performance. I would appreciate your feedback on my analysis.
NLong
by KAPRUKA
3
NRXP 1D - Swing PositionNRXP 1D - Swing Position - Not reco to buy/sell Extreme volatility has been seen consistently in the bio-sectors as seen the chart in the above analysis - NXRP has received consistently positive news regarding their primary drug ZYESAMI and the clinical trials they are actively participating in. Profile : NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behaviour. The company was founded in 2015 and is based in Wilmington, Delaware. GLTA!!
NLong
by hoodchef
1
$NRXP entry PT 14.50-14.75 PT 60 and higher...timeline 09/14/202NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NLong
by BADQOMOCAWGOWLD
NRXP | in search for the next MRNA After a perfect touch of the .618 Fib retracement level, now NRXP is ready to aim higher! Get ready for action! My first price target is 35usd. Today NRx was granted Fast Track Designation by the U.S. Food and Drug Administration for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure! NRx Pharmaceuticals has also a Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife COVID Vaccine. NRx Pharmaceuticals has Successful Commercial Formulation for ZYESAMI (aviptadil) and Stockpiling of COVID-19 Medication Subject to Regulatory Approval. ZYESAMI Helps Prevent "Cytokine Storm" in Patients with COVID-19
NLong
by TopgOptions
Do you have Diamond Hands? Check out NXRP's Volatile Reversal...NRXP is in for a wild & volatile ride where it may reverse & double in value or even more. Technicals support a reversal over weeks with a current strong trend on the daily. Fundamentals are strong; F-Score is 9 & they just had some major news catalysts including a COVID-19 Treatment drug. High risk with potentially high reward: up to a 25% drawdown and a potential 100+% gain leading to a 4:1 risk to reward ratio. With a ~30% short interest this could be a wild ride like GME or AMC. Risk management by day trading may be possible.
NLong
by jsgiardino
Next Levels For NRXPFollowing up with the NRXP levels from earlier this month, it looks like before it reaches the 618 fib line, there's a pretty clear area of high traffic that has acted as both support and resistance over the last few months. That happens to sit right around the $28-$30 area. Aftermarket on Friday, NRXP failed to hold above it and settled back down just shy of $27. With 2 big volume days on the front end of this move, it will be interesting to see if this same area will act as resistance or if NRXP can firmly push back above it to possibly test the 618 fib level. Also, the 200DMA may be an interesting technical trend line to follow to see if it ultimately acts as a new support for the stock. "According to the company, 'In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI™ had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the study.'...The data were submitted to the FDA as a supplement to its pending Emergency Use Authorization application. The company has also planned on submitting a biomarker letter of intent to the FDA. NRX has explained that cytokine release syndrome or “cytokine storm” has been related to mortality in a number of conditions including Acute Respiratory Distress Syndrome. Since these data also have to do with a pending EUA application for ZYESAMI, Wednesday’s further details may be something to keep mindful of heading into the week." Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
N
by PennyStocks101
NRXP - Game of Pscycology ? Use good money management to win Note : If you have any questions, feel free to send me message Please give your comment/idea. Thanks Greetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox). Pra Trading : - Please care for Money Management - Have a good psychology - Do not be hurry to open position and do not do nothing if u see opportunity - Evaluate and upgrade your trading plan Execution Strategy : - Know what you want to buy, see the Fundamental - Decide that you are on investing or speculating - Consider what your strategy based on Investing/Speculating - Make Road Map Of Your Trading Plan - Decide a. Entry strategy b. Cut loss c. Target of Profit Post Trading : a. Do not be sad if you loss or do not be very happy if you win b. Just become a normal without emotion, Do not put emotion into your trading c. Evaluate your trading d. Keep on Learning e. Be Humble Idea : NRXP - Game of Pscycology ? Use good money management to win ------------------------------------------ About Us : MultiAssetXplorations is traders that explore and trade multi asset such as Stock, Forex, Crypto, Options, Future, Commodities , Indice, etc. If you have any
N
by MultiAssetX
1
$NRXP entry PT 8.50-9 Long term PTs 40-50 and higher$NRXP entry PT 8.50-9 Long term PTs 40-50 and higher WAVE ANALYSIS SUPPORT AND RESISTANCE NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NLong
by BADQOMOCAWGOWLD
2
Not Much Fib With NRXP But Levels, Yes!Fib Retracement on NRXP doesn't show much by way of "important levels" until you get to the 786 if you use that ATH for the top of your fib set-up. BUT if you look back on the chart, there's a pretty clear level right AT the area NRXP stock is trading at after this news. Around $12.70 was a previous area where the stock tested but didn't break below. Now, since breaking below, this seems to be a level that it can't break above. However, after the news came out, NRXP has treaded water between 11.50 & $12 in a consolidation trend during the 7/19 session. Volume will be something to keep an eye on moving forward in deciding which way it will break. "Shares of NRXP were also going against the grain of the broader biotech trend at the start of the week. NRX Pharmaceuticals (NRXP Stock Report) announced that it will present data at the Disease Control and Prevention Summit this week. Wednesday (7/21) the company provides evidence that its YESAMI treatment might help prevent “cytokine storm” in patients with COVID-19. According to the company, 'In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI™ had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the study.'” Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
N
by PennyStocks101
NRXP_52weeklowNRXP is reaching its 52week low and what goes down must go up & vice-versa in the market...the long wick inverted candle looks like this may have some momentum on the upside if the phase 2 and 3 trials go well for is COVID-19 lung respiratory issues and Bipolar acute suicide medication will be useful for both mental and physiological health...stochastic looks like it is making movements but the momentum is on a flag but an uptick...Very volatile and FDA approval will be the major factor for this stock as it returns to its 52 week low...only long due to the technicals but phase 2 & 3 trials will be the major growth/mom factor for this stock...
NLong
by CrookedTREE_FINTECH
1